The US Food and Drug Administration has allowed marketing of ClearLLab Reagents (T1, T2, B1, B2, M), the first agency authorised test for use with flow cytometry to aid in the detection of several leukaemias and lymphomas, including chronic leukaemia,...
from #AlexandrosSfakianakis via Alexandros G.Sfakianakis on Inoreader http://ift.tt/2uVaGHh
via IFTTT
Εγγραφή σε:
Σχόλια ανάρτησης (Atom)
Δημοφιλείς αναρτήσεις
-
Purpose. To evaluate the diagnostic performance of the McMonnies questionnaire as a screening survey for dry eye in Chinese outpatients. Met...
-
Abstract Background With the development of emergency and intensive medical technologies, the survival rate of traumatic brain injury ha...
-
Abstract Blinatumomab is a bispecific T-cell engaging αCD19 antibody used in refractory or relapsed B-cell precursor acute lymphoblastic l...
-
Malignant peripheral nerve sheath tumor (MPNST) is the leading cause of mortality in patients with neurofibromatosis type 1. In 2002, an MPN...
-
Abstract Background While dietary factors have been shown to play an important etiologic role in non-Hodgkin lymphoma (NHL), little is k...
-
Background: Paget disease, Bowen disease, and malignant melanoma in situ are intraepidermal neoplasms, characterized by the presence of page...
-
Exposure to asbestos is the main cause of malignant pleural mesothelioma (MPM), a highly aggressive cancer of the pleura. Since the only too...
-
<span class="paragraphSection"><div class="boxTitle">Background</div>In Australia, high uptake of the ...
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου